These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 36731587)

  • 21. The burden cost of French patients suffering from irritable bowel syndrome.
    Le Pen C; Ruszniewski P; Gaudin AF; Amouretti M; Bommelaer G; Frexinos J; Poynard T; Maurel F; Priol G; Bertin C
    Scand J Gastroenterol; 2004 Apr; 39(4):336-43. PubMed ID: 15125465
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comprehensive assessment of patients with irritable bowel syndrome with constipation and chronic idiopathic constipation using deterministically linked administrative claims and patient-reported data: the Chronic Constipation and IBS-C Treatment and Outcomes Real-World Research Platform (CONTOR).
    Taylor DCA; Abel JL; Martin C; Doshi JA; Essoi B; Korrer S; Reasner DS; Carson RT; Hunter AG
    J Med Econ; 2020 Oct; 23(10):1072-1083. PubMed ID: 32696684
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Patients suspected of irritable bowel syndrome--cross-sectional study exploring the sensitivity of Rome III criteria in primary care.
    Engsbro AL; Begtrup LM; Kjeldsen J; Larsen PV; de Muckadell OS; Jarbøl DE; Bytzer P
    Am J Gastroenterol; 2013 Jun; 108(6):972-80. PubMed ID: 23419383
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Irritable bowel syndrome: epidemiology/economic burden].
    Dapoigny M
    Gastroenterol Clin Biol; 2009 Feb; 33 Suppl 1():S3-8. PubMed ID: 19303536
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Health-related quality of life and health care costs in severe, refractory irritable bowel syndrome.
    Creed F; Ratcliffe J; Fernandez L; Tomenson B; Palmer S; Rigby C; Guthrie E; Read N; Thompson D
    Ann Intern Med; 2001 May; 134(9 Pt 2):860-8. PubMed ID: 11346322
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Economic burden of schizophrenia: empirical analyses from a survey in Thailand.
    Phanthunane P; Whiteford H; Vos T; Bertram M
    J Ment Health Policy Econ; 2012 Mar; 15(1):25-32. PubMed ID: 22611090
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevalence and impact of faecal incontinence among individuals with Rome IV irritable bowel syndrome.
    Goodoory VC; Ng CE; Black CJ; Ford AC
    Aliment Pharmacol Ther; 2023 May; 57(10):1083-1092. PubMed ID: 36914979
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Total costs of IBS: employer and managed care perspective.
    Cash B; Sullivan S; Barghout V
    Am J Manag Care; 2005 Apr; 11(1 Suppl):S7-16. PubMed ID: 15926759
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of chronic constipation on health-related quality of life and work productivity in Japan.
    Tomita T; Kazumori K; Baba K; Zhao X; Chen Y; Miwa H
    J Gastroenterol Hepatol; 2021 Jun; 36(6):1529-1537. PubMed ID: 33047825
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Economic evaluation of linaclotide for the treatment of adult patients with irritable bowel syndrome with constipation in the United States.
    Huang H; Taylor DC; Carson RT; Sarocco P; Friedman M; Munsell M; Blum SI; Menzin J
    J Med Econ; 2015 Apr; 18(4):283-94. PubMed ID: 25333331
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Societal costs for irritable bowel syndrome--a population based study.
    Hillilä MT; Färkkilä NJ; Färkkilä MA
    Scand J Gastroenterol; 2010 May; 45(5):582-91. PubMed ID: 20166844
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A case-control comparison of direct healthcare-provider medical costs of chronic idiopathic constipation and irritable bowel syndrome with constipation in a community-based cohort.
    Herrick LM; Spalding WM; Saito YA; Moriarty J; Schleck C
    J Med Econ; 2017 Mar; 20(3):273-279. PubMed ID: 27783533
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of Rome IV irritable bowel syndrome on work and activities of daily living.
    Goodoory VC; Ng CE; Black CJ; Ford AC
    Aliment Pharmacol Ther; 2022 Sep; 56(5):844-856. PubMed ID: 35794733
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The comparative economic burden of mild, moderate, and severe fibromyalgia: results from a retrospective chart review and cross-sectional survey of working-age U.S. adults.
    Chandran A; Schaefer C; Ryan K; Baik R; McNett M; Zlateva G
    J Manag Care Pharm; 2012; 18(6):415-26. PubMed ID: 22839682
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Irritable bowel syndrome in France: quality of life, medical management, and costs: the Encoli study.
    Brun-Strang C; Dapoigny M; Lafuma A; Wainsten JP; Fagnani F
    Eur J Gastroenterol Hepatol; 2007 Dec; 19(12):1097-103. PubMed ID: 17998835
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Upper gastrointestinal endoscopic findings in functional constipation and irritable bowel syndrome diagnosed using the Rome IV criteria: a cross-sectional survey during a medical check-up in Japan.
    Otani K; Watanabe T; Takahashi K; Nadatani Y; Ominami M; Fukunaga S; Hosomi S; Kamata N; Tanaka F; Nagami Y; Taira K; Kimura T; Fukumoto S; Fujiwara Y
    BMC Gastroenterol; 2023 May; 23(1):140. PubMed ID: 37138209
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quality of life of patients with irritable bowel syndrome is low compared to others with chronic diseases.
    ten Berg MJ; Goettsch WG; van den Boom G; Smout AJ; Herings RM
    Eur J Gastroenterol Hepatol; 2006 May; 18(5):475-81. PubMed ID: 16607141
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Type, rather than number, of mental and physical comorbidities increases the severity of symptoms in patients with irritable bowel syndrome.
    Lackner JM; Ma CX; Keefer L; Brenner DM; Gudleski GD; Satchidanand N; Firth R; Sitrin MD; Katz L; Krasner SS; Ballou SK; Naliboff BD; Mayer EA
    Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1147-57. PubMed ID: 23524278
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tegaserod treatment for IBS: a model of indirect costs.
    Smith DG; Barghout V; Kahler KH
    Am J Manag Care; 2005 Apr; 11(1 Suppl):S43-50. PubMed ID: 15926763
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The spectrum of irritable bowel syndrome: A clinical review.
    Gilkin RJ
    Clin Ther; 2005 Nov; 27(11):1696-709. PubMed ID: 16368443
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.